G-CSF

Links to news articles on G-CSF .

Chemokine Therapeutics announces 2005 financial and operating ... -- 30 Mar 2006
...cancer compound, CTCE-9908, in the treatment of cancer and inhibition of ... and in combination with granulocyte colony stimulating factor (G-CSF); - Completion of ... MSN Money

Taxotere (Docetaxel) Receives US FDA Approval For Use In Advanced ... -- Mar 23, 2006
Locally advanced or metastatic stomach cancer has a poor prognosis with a ... use of growth factor support (granulocyte-colony stimulating factor, G-CSF) was not ... DG News

TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... -- Mar 23, 2006
...occurred in 12 percent of patients receiving secondary prophylactic G-CSF compared to ... United States in four different tumor types: In Breast Cancer: * In the ... PR Newswire (press release),

TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... -- Mar 23, 2006
...occurred in 12 percent of patients receiving secondary prophylactic G-CSF compared to ... In Breast Cancer: * In the United States TAXOTERE® is approved for the ... Yahoo! News (press release)

TAXOTERE Receives US FDA Approval For Use In Advanced Stomach ... -- Mar 23, 2006
...neutropenia and/or neutropenic infection occurred in 12 percent of patients receiving secondary prophylactic G-CSF compared to 28 ... "Stomach cancer claims the ... PharmaLive.com (press release),

Manhattan Nuclear Nightmare -- Mar 19, 2006
Sold by Amgen of Thousand Oaks, California, to treat neutrophil loss caused by cancer therapy, G-CSF works by preventing the death of the bone-marrow precursor ... Archinect

Zenyth Announces in-licensing Agreement -- Feb 28, 2006
...the Ludwig Institute for Cancer Research (LICR) patents to antibodies that target the receptor for the cytokine granulocyte colony stimulating factor (G-CSF). ... PharmaLive.com (press release),

Granulocyte-Colony Stimulating Factor -- Feb 28, 2006
...marrow cells that produce white blood cells, in addition to killing cancer cells. ... They may prescribe G-CSF to increase the number of neutrophils and reduce the ... Journal of American Medical Association (subscription),

Heart-attack patients not helped by Amgen drug -- Mar 1, 2006
Neupogen is used by cancer patients undergoing chemotherapy to build up ... Neupogen is granulocyte colony-stimulating factor, or G-CSF, produced using recombinant ... Ventura County Star (subscription),

Stem Cell Therapy for Heart Disease - Effective Treatments are ... -- Mar 7, 2006
...not use stem cells, but a well-known molecule used in cancer patients to ... Some experts believe that the G-CSF method might not have been effective because it ... PR Web (press release),

Pharmaceutical Companies Feel Threatened by Novel Cures -- Mar 8, 2006
Bru has assured that they have opened a new path to the cure of cancer. ... companies is the simplicity of the solution they are proposing: G-CSF, a medicament ... Periódico 26,

Dacogen™ Improves Outcomes in Myelodysplastic Syndromes -- Mar 15, 2006
This study appeared in an early online publication in Cancer on March 10 ... erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF, Neupogen®) are ... Cancer Consultants (press release),

Ranbaxy enters into a strategic alliance with Zenotech -- Mar 10, 2006
...the world, Ranbaxy will endeavour towards providing access to cancer therapy drugs in ... Zenotech' s generic biologicals, GM-CSF and G-CSF have completed clinical ... Moneycontrol.com,

Chemokine Therapeutics to present phase 1 clinical data at the ... -- Jan 10, 2006
...treatment, effective strategies in addition to G-CSF are needed to prevent and manage infectious complications in neutropenic cancer patients," said Dr. Hassan ... CNW Telbec (Communiqués de presse),

Lipoxen plc lists on AIM raising £3.78million -- Jan 17, 2006
...for patients being treated for kidney failure, hepatitis C and cancer. ... including erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) and a ... Biotech Intelligence (press release),

On the threshold of biotech revolution -- Jan 1, 2006
...on four biotech categories namely - EPO products, Human Insulin, Interferons and G-CSF. ... the discovery of drugs related to diseases such as cancer and diabetes. ... Financial Express,

Chemokine initiates phase Ib trial of lead drug candidate -- Dec 19, 2005
CTCE-0214 to aid in the recovery of a cancer patient's immune ... injection, multi-dose, and in combination with granulocyte colony stimulating factor (G-CSF). ... Pharmaceutical Business Review

Zenotech to launch two bio generics in Feb, plans GDR -- Dec 20, 2005
...in February next two generic biological products, used in cancer therapy ... CSF) and recombinant human granulocyte colony stimulating factor (G-CSF) - are expected ... Newindpress,

AnorMED announces 73 percent of cancer patients who failed prior ... -- Dec 12, 2005
Cancer patients enrolled in the MOZOBIL CUP program failed prior attempts to ... Data reported shows that re-mobilization with MOZOBIL and G-CSF allowed patients ... PR Newswire (press release),

Anormed Announces 73% of Cancer Patients Who Failed Prior ... -- Dec 12, 2005
Cancer patients enrolled in the Mozobil CUP program failed prior attempts to ... Data reported shows that re-mobilization with Mozobil and G-CSF allowed patients ... DG News

Chemokine Therapeutics commences second clinical study for lead ... -- Dec 15, 2005
...injection, multi-dose, and in combination with granulocyte colony stimulating factor (G-CSF). ... the potential to aid in the recovery of a cancer patient's immune ... CNW Telbec (Communiqués de presse),

Roche and Maxygen to Co-Develop Recombinant Factor VIIa ... -- Dec 15, 2005
...is advancing into clinical development in 2006, a novel G-CSF that Maxygen ... leaders in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... PR Newswire (press release),

Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... -- Dec 7, 2005
...options were available to one in which the supportive growth factors erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF, Neupogen®) are ... Cancer Consultants (press release),

No Long-Term Adverse Effects of Neupogen® Given After Allogeneic ... -- Dec 13, 2005
Reference: Khoury HJ, Loberiza FR, Ringden O, et al. Impact of posttransplant G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood . ... Cancer Consultants (press release),

Application for Advanced Gastric Cancer Drug Gets FDA Priority ... -- Dec 2, 2005
...was a 57 percent reduction in Grade 3-4 neutropenia in patients who received G-CSF. ... shows promise in the treatment of advanced stomach cancer," said professor ... EndoNurse,

Vitae Pharmaceuticals Initiates Phase II Clinical Trials for Two ... -- Nov 29, 2005
...of VTP-195183 in combination with Granulocyte Colony Stimulating Factor (G-CSF) to enhance ... shown to be generally safe and well tolerated in cancer patients in ... PR Newswire (press release),

Prophylactic G-CSF Reduces Infection-Related Mortality -- Nov 10, 2005
G-CSFs) reduces the risk of infection-related mortality in cancer patients ... Although prophylactic G-CSF use in high-risk patients has demonstrated a significant ... Cancer Consultants (press release),

MOZOBIL(TM) abstracts accepted for presentation at the American ... -- Nov 15, 2005
...demonstrates that the increased lymphocyte content of a MOZOBIL + G-CSF graft may ... to over 420 patients, and data from over 190 subjects and cancer patients has ... PR Newswire (press release),

Addition of G-CSF Reduces Risk of Febrile Neutropenia in Small ... -- Nov 2, 2005
Among patients with small-cell lung cancer, the combination of antibiotics and granulocyte colony-stimulating factor (G-CSF) is more effective than antibiotics ... Cancer Consultants (press release),

Prophylactic G-CSFs May Reduce Infection-Related Mortality -- Nov 11, 2005
...have reported that the use of prophylactic granulocyte-colony stimulating factor (G-CSF) may reduce the risk of infection-related mortality in cancer patients. ... Cancer Consultants (press release),

AnorMED reports fiscal 2006 second quarter results, and progress ... -- Nov 8, 2005
25 cancer patients undergoing a stem cell transplant, were published in the medical Journal Blood. These results show that MOZOBIL in combination with G-CSF is ... PR Newswire (press release),

Life-threatening Complications From Doxorubicin-Docetaxel ... -- Nov 3, 2005
40%. 7 This needs to be evaluated in terms of cost and benefit since G-CSF is one of the most expensive cancer drugs. Another question ... Journal of American Medical Association (subscription),

Life-threatening Complications From Doxorubicin-Docetaxel ... -- Nov 3, 2005
...standard anthracycline chemotherapy 3 and is now regarded as one of the major adjuvant regimens in early-stage breast cancer. We believe that G-CSF should be ... Journal of American Medical Association (subscription),

AnorMED to Seek Conditional Marketing Authorization in Europe for ... -- Oct 18, 2005
...issue of the peer-reviewed journal, Blood, demonstrates that cancer patients who received MOZOBIL plus granulocyte-colony stimulating factor (G-CSF) were able ... CNW Telbec (Communiqués de presse),

More information on G-CSF from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.